表紙
市場調查報告書

奈米醫藥品:主題研究

Nanopharmaceuticals - Thematic Research

出版商 GlobalData 商品編碼 929729
出版日期 內容資訊 英文 96 Pages
訂單完成後即時交付
價格
奈米醫藥品:主題研究 Nanopharmaceuticals - Thematic Research
出版日期: 2020年03月01日內容資訊: 英文 96 Pages
簡介

不久的將來,奈米醫藥品可望在因應由於人口成長導致的慢性病增加中發揮重要作用。其對像不僅只是癌症,也包含糖尿病、關節炎、CV疾病、阿茲海默症、帕金森氏症等。今後將需要一種副作用少的新治療方法,其能改善生活品質 (QoL) 、提升病患治療效果、減輕基礎醫療負擔、降低住院率。此外,透過使用固有抗菌特性、以及作為抗菌劑的有效藥物傳輸系統,奈米藥物亦具有抵抗抗生素抗藥性威脅的潛力。

本報告研究全球奈米醫藥品市場,彙整產業基本結構、背景情況、主要宏觀因素、整體趨勢和按領域的詳細趨勢、新應用領域的可能性、整體奈米粒子價值鏈中定位、目前課題和未來產業發展展望等情報。

目錄

第1章 目錄

第2章 市場參與企業

第3章 產業趨勢

  • 技術趨勢
  • 宏觀經濟趨勢
  • 監管趨勢
  • 奈米醫藥品對生物醫藥品產業的影響 (展望)

第4章 產業分析

  • 市場規模與成長預測
  • 上市的奈米醫藥品
  • PIPELINE中的奈米醫藥品
  • M&A (企業併購)/策略聯盟
  • 時間軸
  • 案例研討
    • Diasome:以肝細胞為標靶的微脂體添加劑 - 提升胰島素功效和安全性
    • PharmaCyte:基於聚合物的Cell-in-a-Box科技 - 實現低劑量化療
    • Kala Pharmaceuticals:基於奈米結晶的AMPPLIFY科技 - 藥物粒子穿透黏液屏障,大幅增加以眼部組織為標的的藥物傳輸
    • Celgene:Abraxane (紫杉醇的蛋白素結合奈米製劑) - 降低其游離型毒性
    • Oasmia Pharmaceuticals:XR17微胞技術 - 無須前置處方的縮短化療輸注時間
    • Alnylam:Onpattro (基於脂質奈米科技) - 第一個獲得核准的RNAi治療藥物
    • Starpharma:DEP科技 (基於樹枝狀聚合物) - 改善功效並降低主要化學藥劑相關毒性
    • Nanobiotix:Hensify (First-in-Class放射線治療提升劑):利用無機氧化鉿奈米粒子擴大放射線治療效果
    • 第一三共:Enhertu (抗體藥物複合體) - 提供轉移性乳癌的新治療選擇

第5章 價值鏈

  • 奈米粒子
    • 微脂體奈米粒子
    • 高分子奈米粒子
    • 奈米結晶
    • 蛋白質奈米粒子
    • 脂質奈米粒子
    • 微胞
    • 樹枝狀聚合物
    • 無機奈米粒子
    • 免疫接合物
    • 奈米乳液

第6章 企業

  • 上市公司
  • 非上市公司

第7章 縮略語

第8章 附錄

目錄
Product Code: GDHCHT049

Nanomedicine is the application of nanotechnology for the diagnosis, prevention, and treatment of disease. This report will focus on the use of nanomedicines for drug delivery and therapeutic purposes, which are often referred to as nanopharmaceuticals, nanodrugs, or nanotherapeutics. Nanopharmaceuticals are defined as drugs or biologics that have been combined with certain synthetic or biological delivery systems, or nanocarriers, in order to impart physical and biological advantages over conventional medicines.

These include enhanced efficacy, reduced toxicity, improved solubility and stability, improved PK/PD, increased circulation time, targeted controlled release and tissue selectivity, and increased intracellular concentration.

The vast majority of marketed and pipeline nanopharmaceuticals are being used to treat a wide range of cancer indications, highlighting the ongoing unmet needs in this area. Other therapy areas include infectious diseases, cardiovascular (CV) and metabolic conditions, ophthalmology, and rare diseases.

A significant proportion of pipeline candidates are in Phase I or Phase II (65%), and almost 70% of the companies are either start-ups or small biopharmaceutical companies. This represents significant opportunities for mergers and acquisitions (M&As) or licensing agreements with larger pharmaceutical companies looking to either invest in innovative nanotechnology or bolster their pipelines with novel therapies.

Novel nanopharmaceuticals allow the implementation of personalized and precision medicine, particularly in cancer. This includes immunoconjugates and the use of nanomaterials as carriers for ribonucleic acid interference (RNAi)-based therapies. Some smart nanocarriers release a drug when triggered by internal or external stimuli, while nano-radioenhancers use the inherent properties of inorganic nanomaterials to treat tumors using local hyperthermia.

In the near future, nanopharmaceuticals will play a key role in the fight against the rise of chronic diseases due to the growing aging population. As well as cancer, this includes diabetes, arthritis, CV disease, Alzheimer's disease, and Parkinson's disease. There is a need for new treatments with reduced side effects that can improve quality of life (QoL), leading to improved patient outcomes, reduced burden on primary care, and reduced hospitalizations.

Nanomedicine also has the potential to combat the threat of antibiotic resistance via the use of nanomaterials with intrinsic antibacterial properties, as well as using nanoparticles as effective drug delivery systems for antibacterial agents.

Scope

The Nanopharmaceuticals report provides an assessment of the key industry trends impacting how nanopharmaceuticals are being used in healthcare today, including technological, regulatory, and macroeconomic themes.

Components of the report include -

  • Key Industry Players - the big players in the nanopharmaceuticals industry and where they sit in the value chain.
  • Trends in the nanopharmaceutical space - key trends impacting the use of nanopharmaceuticals classified into technology, macroeconomic, and regulatory themes.
  • Industry Analysis - market value of marketed and pipeline nanopharmaceuticals to 2025, as well as a breakdown of nanopharmaceuticals by branded or generic product, phase of development, type of company, and route of administration. Key M&A and licensing agreements in the nanopharmaceutical space are also included, as well as case studies showing examples of the different types of nanopharmaceuticals and their application.
  • Value Chain - Leaders and challengers by nanopharmaceutical type

Reasons to Buy

  • Develop business strategies by understanding how nanotechnology is being used in the healthcare today and how this technology is expected to affect the healthcare sector in the future.
  • Stay up to date on the industry's big players in nanopharmaceuticals and where they sit in the value chain.
  • Identify emerging industry trends to gain a competitive advantage.
  • Identify pipeline targets for M&A and licensing opportunities.

Table of Contents

1 Table of Contents

  • 1.1 List of Tables
  • 1.2 List of Figures

2 Industry Players

3 Industry Trends

  • 3.1 Technology Trends
  • 3.2 Macroeconomic Trends
  • 3.3 Regulatory Trends
  • 3.4 Expected Impact of Nanomedicines on the Biopharmaceutical Industry in 2020

4 Industry Analysis

  • 4.1 Market Size and Growth Forecasts
  • 4.2 Marketed Nanopharmaceuticals
  • 4.3 Pipeline Nanopharmaceuticals
  • 4.4 Mergers, Acquisitions, and Strategic Alliances
  • 4.5 Timeline
  • 4.6 Case Studies
    • 4.6.1 Targeting Liver Cells with Diasome's Liposomal Additive Improves the Efficacy and Safety of Insulins
    • 4.6.2 PharmaCyte's Polymer-Based Cell-in-a-Box Technology Allows the Administration of Lower Doses of Chemotherapy
    • 4.6.3 Kala Pharmaceuticals' Nanocrystal-Based AMPPLIFY Technology Allows Drug Particles to Penetrate Mucus Barriers and Significantly Increase Drug Delivery to Target Eye Tissues
    • 4.6.4 Celgene's Abraxane, an Albumin-Bound Nanoformulation of Paclitaxel, Reduces the Toxicity Associated with Its Free Form
    • 4.6.5 Oasmia Pharmaceuticals' XR17 Micelle Technology Allows for Shorter Infusions of Chemotherapy with No Premedication Required
    • 4.6.6 Alnylam's Onpattro, Based on Lipid Nanotechnology, Is the First RNAi Therapeutic to Receive Approval
    • 4.6.7 Starpharma's Dendrimer-Based DEP Technology Improves Efficacy and Reduces Toxicity Associated with Leading Chemotherapy Drugs
    • 4.6.8 Nanobiotix's Hensify, a First-in-Class Radioenhancer, Utilizes Inorganic Hafnium Oxide Nanoparticles to Amplify the Effects of Radiation Treatment
    • 4.6.9 Daiichi Sankyo's Antibody-Drug Conjugate Enhertu Offers a Novel Treatment Option for Metastatic Breast Cancer

5 Value Chain

  • 5.1 Nanoparticles
    • 5.1.1 Liposomal Nanoparticles
    • 5.1.2 Polymeric Nanoparticles
    • 5.1.3 Nanocrystals
    • 5.1.4 Protein Nanoparticles
    • 5.1.5 Lipid Nanoparticles
    • 5.1.6 Micelles
    • 5.1.7 Dendrimers
    • 5.1.8 Inorganic Nanoparticles
    • 5.1.9 Immunoconjugates
    • 5.1.10 Nanoemulsions

6 Companies

  • 6.1 Public Companies
  • 6.2 Private Companies

7 Abbreviations

8 Appendix

List of Tables

  • Table 1: Technology/Scientific Trends
  • Table 2: Macroeconomic Trends
  • Table 3: Regulatory Trends
  • Table 4: M&As in the Nanopharmaceutical Industry
  • Table 5: Strategic Alliances in the Nanopharmaceutical Industry
  • Table 6: Approved

List of Figures

  • Figure 1: The Leaders and Challengers in the Nanopharmaceutical Value Chain
  • Figure 2: Pharma Executives Do Not Expect Nanomedicine to Have a High Impact on the Industry in 2020
  • Figure 3: Market Forecast by Nanopharmaceutical Type, 2018-202